Stock screener

TSHA

Conviction 61HealthcareScan · Mon, Aug 10, 2026
TSHA$6.38-2.82%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 2.51M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Taysha Gene Therapies, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.tayshagtx.com
Price6.38
Change-2.82%
Gap-3.96%
Rel volume1.40×
Avg volume2.76M
Avg $ vol16.39M
SMA 205.91
SMA 506.04
SMA 2005.29
Price vs 50+5.62%
Price vs 200+20.49%
MA stackbullish
50/200 cross
Supertrenddown · 6.77
RSI (14)56
MACD hist0.10
MACD crossbull · 5d
Stoch %K / %D84 / 89
ADX (14)14
+DI / −DI21 / 15
RSI divergence
MACD divergenceBullish
ATR %+5.85%
ADR %6.40%
52w high6.98
52w low2.72
From 52w high-8.67%
Above 52w low+134.37%
New 52w highNo
SqueezeOff
Bollinger width22.34%
%B0.85
Donchian pos83.59%
Donchian high6.59
Donchian low5.28
AVWAP (52w high)6.11
vs AVWAP high+4.31%
AVWAP (52w low)4.83
vs AVWAP low+32.06%
OBV trendFlat
Chaikin MF (20)0.17
Today vs 20d1.40×
Avg vol (14d)2.51M
Avg vol (20d)2.76M
Avg $ vol (20d)16.39M
Market cap
RS 3m (vs SPY)-7.35%
RS 6m (vs SPY)+34.64%
RS line new highNo
Trend template7/8
Technical rank81.8
1 week+10.29%
1 month+0.55%
3 months-6.39%
6 months+38.29%
1 year+126.87%
YTD+21.43%
P/E-17.28
P/B8.89
P/S192.74
P/FCF-20.08
EPS-0.3400
Div yield
ROE-51.43%
ROA-36.29%
Debt/Eq0.23
Current14.04
EV/EBITDA
Gross margin
Net margin
Rev growth17.28%
EPS growth-22.06%
Price target12.50
Target upside90.69%
Analyst ratingBuy
Institutional91.15%
Ent. value1.66B
Revenue0
Net income-42.41M
Gross profit
Free cash flow-93.83M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out287.36M
Employees99
ListedThu, Sep 24, 2020
Free float
Float %
Short interest
Days to cover
Short volume
Squeeze score
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeB
Conviction61 / 100
Pattern quality
Tech rank81.8 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance7.09
Support5.30
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in TSHA

All disclosures →
No recent disclosed trades by Congress in TSHA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in TSHA · 8 buys · 1 sell

InsiderSideShares
Nagendran Sukumar
President and Head of R&D · Common Stock · 2026-07-10
Sell200K
Stalfort John A III
Director · Common Stock · 2026-06-01
Grant21.34K
Donenberg Phillip B.
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K
Stalfort John A III
Director · Common Stock · 2026-06-01
Other
Long Alison S
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K
Long Alison S
Director · Common Stock · 2026-06-01
Grant21.34K
Stalfort John A III
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K
Sepp-Lorenzino Laura
Director · Common Stock · 2026-06-01
Grant21.34K
Donenberg Phillip B.
Director · Common Stock · 2026-06-01
Grant21.34K
Sepp-Lorenzino Laura
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K

SEC filings

EDGAR filings in TSHA · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.